1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 7,200 | 7,500 | 09:58 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 31.12.25 | HENLIUS (02696): POLL RESULTS OF THE RESOLUTION PROPOSED AT THE 2025 FOURTH EXTRAORDINARY GENERAL MEETING HELD ON WEDNESDAY, 31 DECEMBER 2025 | 3 | HKEx | ||
| 31.12.25 | HENLIUS (02696): CONTINUING CONNECTED TRANSACTIONS | 1 | HKEx | ||
| 29.12.25 | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT HAS BEEN DOSED IN A PHASE 1 CLINICAL STUDY OF HLX37 (RECOMBINANT HUMANISED ANTI-PD-L1 AND ... | 4 | HKEx | ||
| 23.12.25 | Henlius CEO Dr. Jason Zhu to Deliver a Keynote Presentation at JPM 2026 | 660 | PR Newswire | SHANGHAI, Dec. 23, 2025 /PRNewswire/ -- The 44th J.P. Morgan Healthcare Conference will take place from January 12 to 15, 2026, in San Francisco, USA. Dr. Jason Zhu, Executive Director and... ► Artikel lesen | |
| 19.12.25 | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - THE INVESTIGATIONAL NEW DRUG APPLICATION FOR THE PHASE 1 CLINICAL TRIAL OF NIVOLUMAB BIOSIMILAR HLX18 (RECOMBINANT ... | 4 | HKEx | ||
| 12.12.25 | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION (NDA) FOR HANSIZHUANG (SERPLULIMAB INJECTION) IN COMBINATION WITH CHEMOTHERAPY FOR NEO-/ ... | 1 | HKEx | ||
| 09.12.25 | Alligator Bioscience Comments on Henlius Receiving Regulatory Approval in China to Initiate Phase 2/3 Trials of HLX22 in HER2-Positive Breast Cancer | 312 | ACCESS Newswire | LUND, SE / ACCESS Newswire / December 9, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX)(STO:ATORX) today comments on the announcement by Shanghai Henlius Biotech, Inc. that applications for Phase... ► Artikel lesen | |
| SHANGHAI HENLIUS BIOTECH Aktie jetzt für 0€ handeln | |||||
| 09.12.25 | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - APPLICATIONS FOR PHASE 2/3 CLINICAL TRIALS OF HLX22 (RECOMBINANT HUMANISED ANTI-HER2 MONOCLONAL ANTIBODY INJECTION) ... | 1 | HKEx | ||
| 03.12.25 | HENLIUS (02696): PROXY FORM FOR THE 2025 FOURTH EXTRAORDINARY GENERAL MEETING TO BE HELD ON 31 DECEMBER 2025 (OR ANY ADJOURNMENT THEREOF) | - | HKEx | ||
| 03.12.25 | HENLIUS (02696): NOTICE OF EXTRAORDINARY GENERAL MEETING | 1 | HKEx | ||
| 03.12.25 | HENLIUS (02696): CONTINUING CONNECTED TRANSACTIONS RENEWAL OF THE SINOPHARM DISTRIBUTION COLLABORATION AND NOTICE OF EXTRAORDINARY GENERAL MEETING | 2 | HKEx | ||
| 03.12.25 | HENLIUS (02696): CONTINUING CONNECTED TRANSACTIONS - RENEWAL OF THE SINOPHARM DISTRIBUTION COLLABORATION | 1 | HKEx | ||
| 03.12.25 | HENLIUS (02696): CONNECTED TRANSACTION AND CONTINUING CONNECTED TRANSACTIONS - COLLABORATION AGREEMENTS WITH AVANC PHARMA FOR FOVINACICLIB CITRATE CAPSULES | - | HKEx | ||
| 02.12.25 | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION (NDA) FOR BIOSIMILAR OF DENOSUMAB HLX14 (RECOMBINANT ANTI-RANKL HUMAN MONOCLONAL ANTIBODY ... | 2 | HKEx | ||
| 01.12.25 | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - THE INVESTIGATIONAL NEW DRUG APPLICATION OF HLX37 (RECOMBINANT HUMANISED ANTI-PD-L1 AND ANTI-VEGF BISPECIFIC ... | - | HKEx | ||
| 25.11.25 | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - FIRST PATIENT HAS BEEN DOSED IN AN INTERNATIONAL MULTICENTER PHASE 1 CLINICAL STUDY OF IPILIMUMAB BIOSIMILAR ... | 1 | HKEx | ||
| 20.11.25 | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - HANSIZHUANG (SERPLULIMAB INJECTION) IN COMBINATION WITH CHEMOTHERAPY FOR NEO-/ADJUVANT TREATMENT FOR GASTRIC ... | - | HKEx | ||
| 18.11.25 | Organon & Co.: Henlius und Organon geben die Zulassung von POHERDY (Pertuzumab-dpzb) durch die US-amerikanische Arzneimittelbehörde FDA bekannt, dem ersten PERJETA (Pertuzumab)-Biosimilar in den USA | 701 | Business Wire | Shanghai Henlius Biotech, Inc. (2696.HK) und Organon (NYSE: OGN) gaben heute bekannt, dass die US-amerikanische Arzneimittelbehörde FDA (Food and Drug Administration) den Antrag auf Zulassung von... ► Artikel lesen | |
| 17.11.25 | Henlius and Organon score first US Perjeta biosimilar approval | 18 | Pharmaceutical Technology | ||
| 14.11.25 | Organon and Henlius' Poherdy, first biosimilar to Roche's Perjeta, scores FDA nod | 26 | FiercePharma |
1 2 3 4 Weiter >>
69 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 294,38 | 0,00 % | Praxis Precision Medicines appoints new board members, promotes executives | ||
| APOGEE THERAPEUTICS | 77,48 | -1,86 % | Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and ... | Phase 1b interim results of zumilokibart (APG777) in asthma demonstrated rapid and durable suppression of FeNO (key biomarker of Type 2 inflammation) through 16 weeks for all patients - Suppression... ► Artikel lesen | |
| VENTYX BIOSCIENCES | 13,830 | +0,73 % | Ventyx Biosciences und BioAge Labs: Tenbagger-Rendite im No Brainer Club! | Mit Ventyx Biosciences feiert der No Brainer Club eine waschechte Tenbagger-Empfehlung: Nach Übernahmegerüchten springt die Aktie heute im regulären Handel zunächst um rund 30% nach oben, bevor sie... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 29,880 | +1,01 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 | Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 14,350 | 0,00 % | MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day | MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submission of a Biologic License Application... ► Artikel lesen | |
| VERA THERAPEUTICS | 47,690 | -2,03 % | Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy | FDA assigned PDUFA target action date of July 7, 2026.If approved, atacicept would be the first B cell modulator targeting both BAFF and APRIL for IgAN.Atacicept received FDA Breakthrough Therapy... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 23,280 | 0,00 % | Enliven Therapeutics, Inc.: Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones | Cumulative major molecular response (MMR) rate of 69% by 24 weeks, with 53% of patients achieving MMR by 24 weeks in ongoing randomized Phase 1b cohorts
ELVN-001... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 25,310 | 0,00 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects | In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1/IL-6 driven inflammatory diseases, demonstrated... ► Artikel lesen | |
| COGENT BIOSCIENCES | 35,570 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis | WALTHAM, Mass. and BOULDER, Colo., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined... ► Artikel lesen | |
| BEAM THERAPEUTICS | 28,000 | 0,00 % | Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting | Updated Data from 31 Adult and Adolescent SCD Patients Treated with risto-cel (Formerly BEAM-101) Show Mean Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to Resolution of Anemia... ► Artikel lesen | |
| ALUMIS | 18,170 | 0,00 % | What's Going On With Alumis Stock Thursday? | ||
| STRUCTURE THERAPEUTICS | 66,98 | +1,10 % | Cantor Fitzgerald reiterates Structure Therapeutics stock rating at Overweight | ||
| ERASCA | 5,840 | 0,00 % | What's Going With Cancer Biotech Erasca Stock On Thursday? | ||
| RECURSION PHARMACEUTICALS | 4,700 | -3,29 % | Recursion Pharmaceuticals (RXRX) Climbs 6.8% Ahead of Next Week's Business Updates | ||
| REGENCELL BIOSCIENCE | 41,590 | 0,00 % | Regencell Bioscience is the top performing pharma stock YTD |
SHANGHAI HENLIUS BIOTECH INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,100 (+1,39 %) liegt der Kurs bei 7,300 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHANGHAI HENLIUS BIOTECH INC finden Sie auf Wallstreet Online.